Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Balanol is a natural product isolated from the fungus Verticillium balanoides. It is a potent, non-selective ATP-competitive inhibitor of serine/threonine protein kinases, particularly protein kinase A (PKA) and protein kinase C (PKC), as well as other AGC family kinases. Balanol binds to the catalytic domain of these kinases in a manner similar to ATP, thereby preventing phosphorylation of target substrates and inhibiting downstream signaling pathways. It has also been reported to inhibit G protein-coupled receptor kinases (GRKs), with modest selectivity for GRK2 and GRK3. Balanol was originally discovered during efforts to find novel PKC inhibitors due to the role of PKC overactivation in diseases such as cancer. Preclinical studies have explored its anti-inflammatory, antifungal, and antineoplastic properties; however, development was discontinued for indications including cancer, inflammation, and psoriasis[3][5][6][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on balanol.